Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

Caitlin E. Cox

October 11, 2013

Advertisement

April 2025 Dispatch for the CV Team

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Dapagliflozin Boosts Health Status Across LVEF Range

FDA Approves Empagliflozin for Treatment of HFpEF

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Dapagliflozin Has Benefits Across Heart Failure Subgroups

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content